Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Share-based Compensation (2018 - 2025)

Inmune Bio (INMB) has disclosed Share-based Compensation for 8 consecutive years, with $3.3 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 88.73% to $3.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.9 million through Dec 2025, up 30.26% year-over-year, with the annual reading at $9.9 million for FY2025, 30.31% up from the prior year.
  • Share-based Compensation hit $3.3 million in Q4 2025 for Inmune Bio, up from $3.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $3.3 million in Q4 2025 to a low of -$2.1 million in Q4 2021.
  • Historically, Share-based Compensation has averaged $1.7 million across 5 years, with a median of $1.8 million in 2024.
  • Biggest YoY gain for Share-based Compensation was 453.24% in 2021; the steepest drop was 177.82% in 2021.
  • Year by year, Share-based Compensation stood at -$2.1 million in 2021, then soared by 181.58% to $1.7 million in 2022, then grew by 7.43% to $1.9 million in 2023, then decreased by 6.49% to $1.8 million in 2024, then soared by 88.73% to $3.3 million in 2025.
  • Business Quant data shows Share-based Compensation for INMB at $3.3 million in Q4 2025, $3.0 million in Q3 2025, and $1.5 million in Q2 2025.